

**PRODUCT INFORMATION**

|   |   |
|---|---|
| <b>Common Name</b>                      | IMMU-130, hMN-14-SN-38, hMN-14-SN-38 ADC, hMN14-CL-SN-38, hMN14-SN-38   |
| <b>Synonyms</b>                         | CEACAM-5;CD66e;CEA;Meconium antigen 100   |
| <b>Conjugate</b>                        | Biotinylated  |
| <b>Endotoxin</b>                        | Less than 1.0 EU/ $\mu$ g by the LAL method. For <1 EU/mg requirements, please contact us for customization.  |
| <b>Formulation &amp; Reconstitution</b> | Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.   |
| <b>Delivery</b>                         | In Stock  |
| <b>Host Species</b>                     | Humanized   |
| <b>IgG type</b>                         | Human IgG1 - kappa  |
| <b>Reactivity</b>                       | Human   |
| <b>Target</b>                           | CEACAM5   |
| <b>Uniprot ID</b>                       | P06731  |
| <b>Applications</b>                     | ELISA   |
| <b>Recommended Dilutions</b>            | ELISA 1:5000-10000  |
| <b>Description</b>                      | Biotinylated Anti-CEACAM5 (labetuzumab biosimilar) mAb  |
| <b>Storage&amp;Shipping</b>             | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| <b>Background</b>                       | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.   |
| <b>Usage</b>                            | Research use only   |



## Biotinylated Anti-CEACAM5 (labetuzumab biosimilar) mAb ELISA

0.2  $\mu$ g of Human CEACAM5, His tagged protein per well




Figure 1. ELISA plate pre-coated by 2  $\mu$ g/mL (100  $\mu$ L/well) Human CEACAM5 Protein, His Tag (PME100071) can bind Biotinylated Anti-CEACAM5 (labetuzumab biosimilar) mAb (BME100035B) in a linear range of 40–200 ng/mL.

